67 results about "Ischemic heart" patented technology

The present invention provides a novel method to isolate and expand pure progenitor / stem cells from a primary tissue explant, which produces a population enriched in multipotent functional progenitor / stem cells free of contaminating fibroblasts and other cell types. Cardiac progenitor / stem cells isolated by this method maintain their self-renewal and clonogenic character in vitro and differentiate into normal cells in myocardium, including cardiomyocytes, endothelial cells, and smooth muscle cells, after transplantation into ischemic hearts. The present invention also includes substantially pure populations of multipotent progenitor / stem cells, e.g., cardiac progenitor / stem cells, and their use to treat and prevent diseases and injuries, including those resulting from myocardial infarction.

Methods and devices for increasing revascularization in an ischemic heart and for reducing muscle mass or volume in congestive heart failure patients are described. The method includes using laser energy to create microchannels in the target tissue. The microchannels are separated from each other to maintain tissue that is untreated or undamaged by laser energy. Such undamaged tissue augments angiogenesis. The method also includes delivery of bioactive agents that are angiogenic. The apparatus simultaneously creates a plurality of microchannels that are separated from each other and thereby promote angiogenesis, revascularization and / or muscle reduction.

A system is disclosed for cannulating the vena cava of a patient during cardiopulmonary bypass procedures. Such cannulation is necessary for drainage of venous blood from the patient so that it may be oxygenated and pumped back to the patient to perfuse tissues during cardiac surgery and, more specifically, during periods of ischemic cardiac arrest or dysfunction. The device of the present invention not only provides venous drainage for cardiopulmonary bypass, but also performs the function of routing cardioplegic solution through the heart in the retrograde direction. Such cardioplegia provides protection to the heart during periods of ischemic cardiac arrest. This invention replaces a plurality of cannulae currently used for open-heart surgery, thus simplifying the surgical field and improving visibility of the heart. The device allows for the delivery of retrograde cardioplegia to the coronary circulation of both the right and the left side of the heart. The device further includes protection mechanisms to prevent overinflation or excessive pressurization of the right atrium during retrograde delivery of cardioplegia solution.

The present invention provides a novel method to isolate and expand pure progenitor / stem cells from a primary tissue explant, which produces a population enriched in multipotent functional progenitor / stem cells free of contaminating fibroblasts and other cell types. Cardiac progenitor / stem cells isolated by this method maintain their self-renewal and clonogenic character in vitro and differentiate into normal cells in myocardium, including cardiomyocytes, endothelial cells, and smooth muscle cells, after transplantation into ischemic hearts. The present invention also includes substantially pure populations of multipotent progenitor / stem cells, e.g., cardiac progenitor / stem cells, and their use to treat and prevent diseases and injuries, including those resulting from myocardial infarction.

The invention discloses a heart disease risk prediction system, comprising a computer vision pipeline for processing cardiac ultrasound, wherein the computer vision pipeline for processing cardiac ultrasound comprises a view identification classification, a U-Net convolution neural network for cardiac structure identification, cardiac muscle shape tracking, cardiac muscle shape feature vector extraction, electrocardiogram feature data extraction, clinical feature data extraction, depth learning network architecture and data acquisition and training to predict the probability; Through artificial intelligence to assist automatic ultrasound image recognition and diagnosis, Multidimensional myocardial speckle tracking and prediction of ischemic heart failure were calculated, The combination of medical history, clinical data and biomarkers realizes disease prediction on the machine learning platform, and establishes the first artificial intelligence-assisted accurate, sensitive, efficient,automated and scalable cardiovascular screening system, which realizes low-cost, high-accuracy heart disease prediction and early diagnosis system.

A method is disclosed that enables intra-chamber needle injection treatment using a navigable interventional device. The method includes navigation steps to systematically inject cells, drugs, or other agents in diagnostically identified target tissues, such as ischemic heart wall tissues. Magnetic navigation of a specifically designed needle catheter permits safe access to remote structures of the heart and depth-adaptable needle injections.

The present invention encompasses a liquid bioartificial tissue for restoring tissue and organ function to an injured or damaged organ in a human subject. The liquid bioartificial tissue is injected into a target organ and can significantly restore organ function within two weeks. The invention also encompasses a cell culture medium comprising ascorbic acid (or other free-radical scavengers and / or anti-oxidants) that is used for pre-treating transplantable cells prior to organ transplantation. Pre-treatment with ascorbic acid increases transplanted cell viability and colonization by nearly fifty-fold compared with untreated cells. The invention is particularly useful for treating ischemic heart damage following myocardial infarction.

A method and apparatus are provided for treating cardiac tissue to modulate ischemic heart tissue with topical sub-atmospheric pressure to minimize cell death and damage.

Disclosed is a pharmaceutical composition for the prevention or treatment of ischemic heart diseases, comprising as an active ingredient an inhibitor which acts to restrain mononuclear phagocyte system cells from synthesizing or releasing AGE-albumin, which induces the apoptosis of cardiomyocytes upon the onset of the ischemic heart disease. Also, a method is provided for screening an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells. Inhibitory or suppressive of AGE-albumin-induced cell death, the pharmaceutical composition comprising as an active ingredient an inhibitor against the AGE-albumin synthesis or release of mononuclear phagocyte system cells can be applied to the prevention or treatment of a wide spectrum of ischemic heart diseases including myocardial infarction.

The invention relates to the field of medicinal chemistry, in particular to a photoaffinity labeling marker probe molecule as well as a preparation method and medical application thereof. The probe molecule can be used for selectively marking glycogen phosphorylase in serum, and then the glycogen phosphorylase can be qualitatively and quantitatively detected, so that the probe molecule can be applied to marking detection on a biochemistry marker, namely, glycogen phosphorylase when diseases such as myocardial infarction, angina, arrhythmia, ischemic sudden cardiac arrest and coronary heart disease occur.

A method is provided for the prevention of ischemia / reperfusion injury, for example, in patients undergoing heart surgery, and involves the administration of a phosphodiesterase-5 (PDE-5) inhibitor such as sildenafil. The method may also be used during or after a heart attack to prevent or lessen ischemic heart damage.

The present invention relates to the use of stem cell factor (SCF) for the treatment of ischemic injured tissue such as in cardiovascular disease. The method involves administration of a nucleic acid encoding SCF, wherein the nucleic acid is delivered to the site of the injury and is incorporated into cells which then express the SCF.

The invention relates to the technical field of NMN preparation and discloses a preparation process of high-purity NMN based on an enzymatic method. The preparation process comprises the following steps: (1) raw material pretreatment: performing microfiltration and nanofiltration on nicotinamide ribose at first, and collecting concentrated crude product solution; (2) a production process: enablingthe crude product solution to react under the catalysis of nicotinamide ribokinase or recombinant cells containing the nicotinamide ribokinase to generate beta-nicotinamide mononucleotide; and (3) apurification process: adjusting the pH value of the produced beta-nicotinamide mononucleotide solution to 3-7, sampling the beta-nicotinamide mononucleotide solution on a reversed-phase high-performance liquid chromatography preparation column, and carrying out gradient elution and purification to obtain the purified beta-nicotinamide mononucleotide solution. The preparation process of the high-purity NMN based on the enzyme method ensures the productivity of the nicotinamide mononucleotide, improves the purity of the product, and can make the nicotinamide mononucleotide more obvious in the effect of relieving and improving the injury of ischemic heart and brain tissues. The nicotinamide mononucleotide can better improve oxidation-related degenerative diseases and body dysfunction.

The invention provides an organic extract of Geum japonicum thunb var. (EGJ), and a pharmaceutical composition comprising the same. The organic EGJ has been identified to show potent dual effects on stimulating early growth (less than 48 hours) of new vessels both in ischemic heart muscles and in infracted heart muscles, and on triggering myocardial regeneration in myocardial infarction, and therefore, may be used in the treatment of ischemic diseases in human being or animals including ischemic heart disease and ischemic limbs, and damaged myocardium associated diseases.

The present invention relates to the use of at least one Epac (Exchange Protein directly Activated by cAMP) antagonist for the manufacture of a medicament intended for the prevention or the treatment of pathologies selected from the list comprising cardiac hypertrophy, cardiac arrhythmias, valvulopathies, diastolic dysfunction, chronic heart failure, ischemic heart failure, and myocarditis.

The present invention is related to benzothiophen-2-carbonylguanidine derivatives, a preparation method thereof, and pharmaceutical compositions containing the same. The derivatives have potent inhibitory effect on the sodium / hydrogen exchanger NHE-I, improve the functional recovery of ischemia / reperfusion-induced heart injury in isolated ischemic heart models, and significantly reduce the myocardiac infarct size in in vivo ischemic animal models, thereby showing excellent cardioprotective effects. Also, the derivatives are protective of both neuronal cells and the brain as proven by their protective effects on neuronal cells from necrosis and apoptosis and by their ability to significantly reduce cerebral infarct sizes in in vivo ischemic brain models. The derivatives can be effectively used for the prevention and treatment of ischemic heart diseases such as myocardiac infarction, arrhythmia, angina pectoris and the like, and cerebrovascular diseases such as cerebral stroke and be used as cardioprotective agents to the patients undergoing reperfusion therapy including chemicals such as thrombolytic agents, or surgery such as coronary artery bypass and percutaneous transluminal coronary angioplasty.

A system is disclosed for cannulating the vena cava of a patient during cardiopulmonary bypass procedures. Such cannulation is necessary for drainage of venous blood from the patient so that it may be oxygenated and pumped back to the patient to perfuse tissues during cardiac surgery and, more specifically, during periods of ischemic cardiac arrest or dysfunction. The device of the present invention not only provides venous drainage for cardiopulmonary bypass, but also performs the function of routing cardioplegic solution through the heart in the retrograde direction. Such cardioplegia provides protection to the heart during periods of ischemic cardiac arrest. This invention replaces a plurality of cannulae currently used for open-heart surgery, thus simplifying the surgical field and improving visibility of the heart. The device allows for the delivery of retrograde cardioplegia to the coronary circulation of both the right and the left side of the heart. The device further includes protection mechanisms to prevent overinflation or excessive pressurization of the right atrium during retrograde delivery of cardioplegia solution.

A system and methods are described for improving the management of ischemic cardiac tissue during acute coronary syndromes. The system combines a catheter-based sub-system which allows for simultaneous balloon dilation of a coronary artery and infusion of a carefully controlled perfusate during percutaneous coronary intervention. The system allows for modulation of levels of oxygen at the time of percutaneous intervention. In addition, catheters and systems are provided for administration of fluids with modified oxygen content during an intervention that incorporate upstream flow control members to compartmentalize the perfusion of the target coronary artery and the remainder of the heart.

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.

The invention provides various methods of identifying myocardial infarction (MI) patients who have microvascular obstruction (MO), persistent microvascular obstruction (PMO), reperfusion hemorrhage, iron deposition, chronic iron deposition, and / or fat infiltration / accumulation. The invention provides various methods of identifying myocardial infarction (MI) patients who are at risk of prolonged inflammation burden in heart, adverse cardiac remodeling, electrical abnormality, mechanical abnormality, malignant cardiac arrhythmia, ischemic heart failure, and / or sudden cardiac death. The invention also provides various methods of treating these MI patients with chelation drugs, anti-inflammatory drugs, fat-lowering drugs, cooling therapies, or device therapies, or their combinations.

Disclosed are compositions with sustained-release carriers associated with at least two different types of growth factors and methods of fabrication and treatments thereof. In some embodiments, simultaneous release of the growth factors may be preferred while in other embodiments, sequential release of the growth factors may be preferred. Application of at least two growth factors to an injury site, e.g., compromised cardiac tissue caused by, for example, myocardial infarction or ischemic heart failure, may better mimic and induce the complex growth factor signaling pathways necessary to improve cardiac function. When applied to a patient after a myocardial infarction or ischemic heart failure, multiple growth factors within a sustained-release carrier platform or platforms may cause a synergistic effect on injected cells intending to alleviate left ventricle remodeling. Methods of treatment include percutaneous, sub-xiphoid, and open chest methods using catheters and / or syringes.

The invention discloses a method for building a chronic myocardial ischemia animal model. The method comprises the steps of preparation of sterile operation kit and a small animal respirator; main processes of model building: a mouse is weighed, anesthetized, subjected to atropine hypodermic injection and fixed on a self-made plank platform in a supine position; the neck and chest operation sites are sheared and sterilized through iodophor. The method has the advantages that no mouse is infected through the serious sterile operation in the experiment. The ischemia model is built, ischemia is clear, the myocardial ischemic injury process can be duplicated ideally, and the further study on ischemic heart failure animals, in particular to the study on physiopathologic mechanisms, such as myocardial remodeling after ischemia, is facilitated.

The present invention relates to N-acyl derivatives of amino acids and pharmaceutically acceptable salts thereofwherein n is 2 or 3; andR1 representsor pharmaceutically acceptable salts thereof, to novel processes for preparing the same, to use thereof as anti-allergic, anti-anaphylactic, anti-inflammatory and hypolipidemic agents as well as to a pharmaceutical composition comprising the indicated compounds in an efficient amount and to a method for treating allergic and inflammatory diseases and lipid metabolism disorders: bronchial asthma, allergic rhinitis, pollinoses, seasonal and year-round rhinitis, allergic pneumonitis, atopic dermatitis, psoriasis, urticaria, allergic (including anaphylactic) reactions to insect stings and medicaments, cold allergy, allergic conjunctivitis, atherosclerosis, obesity, ischemic heart and cerebral disease, myocardial infarction and stroke.

The invention discloses a method for building a long-term chronic myocardial ischemia rat model. The method comprises the steps of anesthesia: a small dose of fast-metabolism anesthetic is selected; using a respirator: wherein the use tidal volume is between 2.0 and 4.0ml for 70 times / min; cannula implantation: wherein a cannula is cut open, a plastic tube at the front end of a scalp needle is used, and the incision is required to be big enough; vessel determination: ligation is performed to select the vessel between the left aurcle and the pulmonary artery cone; maintaining of the anatomical structure; monitoring of the mouse state after chest shutting; determining of the ligation effect through the histopathologic slide after the surgery. The method has the advantages that no mouse is infected through the serious sterile operation in the experiment. The ischemia model is built, ischemia is clear, the myocardial ischemic injury process can be duplicated ideally, and the further study on ischemic heart failure animals, in particular to the study on physiopathologic mechanisms, such as myocardial remodeling after ischemia, is facilitated.

In the process of extensively searching for a drug elevating the survival ratio in ischemic heart failure, in particular postinfarction heart failure, it is found out that βARKct which is a βARK1 inhibitor is efficacious not only in improving heart function but also elevating survival ratio in postinfarction heart failure. Accordingly, it is expected that the βARK1 inhibitor is efficaciously usable as a remedy for ischemic heart failure which exerts not only an effect of improving heart function but also another effect of elevating survival ratio and, in its turn, contributes to the improved prognosis in patients with ischemic heart diseases.

The present invention relates to short-acting calcium channel blocking compounds and their use to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension in general, hypertension been.) fore, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.